In 2005, Stallergenes used iBOLT to build an online prescription tracking service that streamlined its back-office information flows. Following this successful implementation, Stallergenes has now launched a new project, once again using Magic’s technology, to
optimize communication between its purchasing and ERP systems. iBOLT linked Stallergenes’ disparate systems, enabling them to automatically convert purchase orders and entries from its Lawson M3 ERP, hosted on an AS/400 server (
IBM System i), before integrating them into the company’s
SAP Financials management system.
“iBOLT serves as the communication hub for our various applications. It is our ‘orchestra conductor’, communicating natively with our various systems,” comments Thierry Gréhaigne, CIO of Stallergenes. “It has enabled us to optimize our workflows, making them reliable and completely transparent for users, whether they are at our French, German, or Italian site.”
“For more than five years now,
iBOLT has enabled us to implement a high-performance, paperless infrastructure,” he adds. “Because it has always been able to safeguard existing systems, we can look ahead to future technological changes with confidence.”
“We are very pleased that Stallergenes has once again chosen Magic Software’s products,” said Guy Bernstein, CEO of Magic Software. “
Magic Software’s iBOLT business integration platform has again proven its ease-of-use and ability to deliver rapid time-to-market integration solutions.”
About Magic Software
Magic Software Enterprises Ltd. (NASDAQ: MGIC), is a global provider of mobile and cloud-enabled application and business integration platforms.
For more information, visit www.magicsoftware.com
About Stallergenes
Stallergenes is a European biopharmaceutical company that focuses on allergenic immunotherapy to treat allergic respiratory illnesses, such as rhinoconjunctivitis, severe rhinitis, and allergic asthma.
A pioneer and leader in sublingual immunotherapy, Stallergenes ploughs more than 20% of its revenue back into R&D, and seeks to develop a new therapeutic classification: sublingual immunotherapy tablets.
In 2010, over 500,000 patients were treated with Stallergenes products.
